Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01901094 · ClinicalTrials.gov registry record · Phase 3
Comparison of Axillary Lymph Node Dissection with Axillary Radiation for Patients with Node-Positive Breast Cancer Treated with Chemotherapy
A Phase 3 study of Stage II Breast Cancer and Stage IIIA Breast Cancer, sponsored by Alliance for Clinical Trials in Oncology.
- Active
- Registry status
- Phase 3
- Development phase
- 2,012
- Enrollment target
- 20
- Study locations
NCT01901094: Active Phase 3 study of Stage II Breast Cancer and Stage IIIA Breast Cancer, sponsored by Alliance for Clinical Trials in Oncology.
NCT01901094 is a Phase 3 study of Stage II Breast Cancer and Stage IIIA Breast Cancer that is active but no longer recruiting, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 2,012 participants, above the 252-participant average among 30 other Stage II Breast Cancer trials with a reported enrollment target (698% higher). The trial reports 20 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01901094, a Phase 3 study of Stage II Breast Cancer and Stage IIIA Breast Cancer, is active but no longer recruiting, sponsored by Alliance for Clinical Trials in Oncology.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 2,012 participants
- Enrollment target
- 20
- Study locations
Study Summary
This randomized phase III trial studies lymph node dissection and radiation therapy to see how well it works compared to radiation therapy alone in treating patients with breast cancer previously treated with chemotherapy and surgery. Lymph node dissection may remove cancer cells that have spread to nearby lymph nodes in patients with breast cancer. Radiation therapy uses high-energy x rays or protons to kill tumor cells. It is not yet known if radiation therapy works better alone or with lymph node dissection in treating patients with breast cancer previously treated with chemotherapy and surgery.
Conditions Studied
Interventions
- PROCEDURE Axillary Lymph Node Dissection (ALND)
- RADIATION Nodal Radiation Therapy
- RADIATION Axillary Radiation Therapy
Study Locations (20)
Alaska
- Anchorage Associates in Radiation Medicine - Anchorage
- Anchorage Radiation Therapy Center - Anchorage
- Alaska Breast Care and Surgery LLC - Anchorage
- Alaska Oncology and Hematology LLC - Anchorage
- Alaska Regional Hospital - Anchorage
- Alaska Women's Cancer Care - Anchorage
- Anchorage Oncology Centre - Anchorage
- Katmai Oncology Group - Anchorage
- Providence Alaska Medical Center - Anchorage
- Fairbanks Memorial Hospital - Fairbanks
Alabama
- Southern Cancer Center PC-Daphne - Daphne
- Mobile Infirmary Medical Center - Mobile
- Southern Cancer Center PC-Mobile - Mobile
- Southern Cancer Center PC-Providence - Mobile
- Southern Cancer Center PC-Springhill - Mobile
- University of South Alabama Mitchell Cancer Institute - Mobile
Arizona
- Arizona Breast Cancer Specialists-Gilbert - Gilbert
- Virginia G Piper Cancer Care-Glendale - Glendale
- Arizona Center for Cancer Care-Peoria - Peoria
- Cancer Center at Saint Joseph's - Phoenix
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,012 participants |
| Start Date | 2014-02-24 |
| Est. Completion | 2026-01-01 |
| Phase | Phase 3 |
What the registry record for NCT01901094 still lists
NCT01901094 is an interventional study that assigns participants to a tested intervention. Its 2,012 participants enrollment target places it among the larger protocols in the corpus, above the 252-participant average among 30 other Stage II Breast Cancer trials with a reported enrollment target (698% higher).
The record links to 2 conditions, with Stage II Breast Cancer appearing as the primary indexed condition, and to 3 interventions - of which Axillary Lymph Node Dissection (ALND) is the first listed.
NCT01901094 names 20 study sites across 3 states, led by Alaska, Alabama, Arizona.
Frequently Asked Questions
What is clinical trial NCT01901094 about?
NCT01901094 is a clinical study titled "Comparison of Axillary Lymph Node Dissection with Axillary Radiation for Patients with Node-Positive Breast Cancer Treated with Chemotherapy". This randomized phase III trial studies lymph node dissection and radiation therapy to see how well it works compared to radiation therapy alone in treating patients with breast cancer previously treated with chemotherapy and surgery. Lymph node dissection may remove cancer cells that have spread to...
What is the current status of trial NCT01901094?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 2,012 participants. The study started on 2014-02-24. Estimated completion is 2026-01-01.
What conditions does trial NCT01901094 study?
This clinical trial studies the following conditions: Stage II Breast Cancer, Stage IIIA Breast Cancer.
What interventions are being tested in trial NCT01901094?
The interventions under investigation include: Axillary Lymph Node Dissection (ALND) (PROCEDURE), Nodal Radiation Therapy (RADIATION), Axillary Radiation Therapy (RADIATION).
Who is sponsoring clinical trial NCT01901094?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01901094 being conducted?
This trial has 20 study locations across Alabama, Alaska, Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage II Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01901094's enrollment target sits among peer trials
2,012 1st of 30 higher than 30 of 30 other Stage II Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Stage II Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy
ACTIVE NOT RECRUITING · Phase 3
-
Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast Cancer
ACTIVE NOT RECRUITING · Phase 3
-
Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery
ACTIVE NOT RECRUITING · Phase 3
-
Combination Chemotherapy and Paclitaxel Plus Trastuzumab in Treating Women With Palpable Breast Cancer That Can Be Removed by Surgery
COMPLETED · Phase 3
-
A Study of Disappearing Markers for Daily Radiation Treatment Delivery for Breast Cancer Patients.
RECRUITING · NA
-
TeleHealth Resistance Exercise Intervention to Preserve Dose Intensity and Vitality in Elder Breast Cancer Patients
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04604509 · 2,010 participants · Phase 4
Nicotine Replacement Therapy, Counseling, Varenicline, and Bupropion for Smoking Cessation, the PISCES I Trial
- NCT04100564 · 2,009 participants · NA
LITES Task Order 0005 Prehospital Airway Control Trial (PACT)
- NCT05059444 · 2,020 participants
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- NCT00001465 · 2,000 participants
Study of the Disease Process of Lymphangioleiomyomatosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI